Pharsight

1. Drug name - ABILIFY MYCITE KIT

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9258035	OTSUKA	Multi-mode communication ingestible event markers and systems, and methods of using the same	Mar, 2029 (6 years from now)
US9060708	OTSUKA	Multi-mode communication ingestible event markers and systems, and methods of using the same	Mar, 2029 (6 years from now)
US8674825	OTSUKA	Pharma-informatics system	Apr, 2029 (6 years from now)
US8956288	OTSUKA	In-body power source having high surface area electrode	Jul, 2029 (6 years from now)
US10441194	OTSUKA	Ingestible event marker systems	Jul, 2029 (6 years from now)
US8945005	OTSUKA	Controlled activation ingestible identifier	Aug, 2029 (6 years from now)
US9433371	OTSUKA	In-body device with virtual dipole signal amplification	Sep, 2029 (6 years from now)
US8718193	OTSUKA	Active signal processing personal health signal receivers	Dec, 2029 (7 years from now)
US9149577	OTSUKA	Body-associated receiver and method	Dec, 2029 (7 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: Method of using a receiver to receive a signal from a tablet embedded with a sensor that communicates information through the body of a patient; Method of using a tablet embedded with a sensor that communicates information via a signal through the body of a patient to a receiver

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription
15MG	TABLET;ORAL	Prescription
20MG	TABLET;ORAL	Prescription
30MG	TABLET;ORAL	Prescription

2. Drug name - ACANYA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9504704	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (6 years from now)
US10220049	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (6 years from now)
US8895070	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (6 years from now)
US10624918	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (6 years from now)
US9561208	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (6 years from now)
US9078870	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (6 years from now)
US10137142	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (6 years from now)
US8663699	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (6 years from now)
US8288434	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Aug, 2029 (6 years from now)

Drugs and Companies using BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE ingredient

Treatment: Treatment of acne vulgaris; topical treatment of acne vulgaris; topical treatment of acne vulgaris in patients 12 years or older; treatment of acne; Topical treatment of acne vulgaris in patients 12 years or older; Treatment of acne; Topical treatment of acne vulgaris; treatment of acne; treatment of acne vulgaris; topical treatment of acne vulgaris; treatment of acne vulgaris; topical treatment of acne vulgaris in patients 12 years or older

Dosage: GEL;TOPICAL

Strength	Dosage	Availability
2.5%;EQ 1.2% BASE	GEL;TOPICAL	Prescription
3.75%;EQ 1.2% BASE	GEL;TOPICAL	Prescription

3. Drug name - ACTOPLUS MET

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9320714	TAKEDA PHARMS USA	Tablet	Feb, 2029 (6 years from now)

Drugs and Companies using METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
500MG;EQ 15MG BASE	TABLET;ORAL	Prescription
850MG;EQ 15MG BASE	TABLET;ORAL	Prescription

4. Drug name - ACUVAIL

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7842714	ALLERGAN	Ketorolac tromethamine compositions for treating ocular pain	Aug, 2029 (6 years from now)
CN103976943B	ALLERGAN	Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain	Mar, 2029 (6 years from now)
CN103976943A	ALLERGAN	Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain	Mar, 2029 (6 years from now)
IN201006461P1	ALLERGAN	Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain	Mar, 2029 (6 years from now)
IN286644B	ALLERGAN	Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain	Mar, 2029 (6 years from now)
EP2257275B1	ALLERGAN	Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain	Mar, 2029 (6 years from now)
EP2446878A1	ALLERGAN	Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain	Mar, 2029 (6 years from now)
EP2257275A2	ALLERGAN	Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain	Mar, 2029 (6 years from now)
EP2446878B1	ALLERGAN	Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain	Mar, 2029 (6 years from now)

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
0.45%	SOLUTION/DROPS;OPHTHALMIC	Prescription

5. Drug name - ALIQOPA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46856	BAYER HEALTHCARE	Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis	Oct, 2029 (7 years from now)

Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
60MG/VIAL	POWDER;INTRAVENOUS	Prescription

6. Drug name - ALUNBRIG

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9273077	TAKEDA PHARMS USA	Phosphorus derivatives as kinase inhibitors	May, 2029 (6 years from now)

Drugs and Companies using BRIGATINIB ingredient

Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)

Dosage: TABLET;ORAL

Strength	Dosage	Availability
30MG	TABLET;ORAL	Prescription
90MG	TABLET;ORAL	Prescription
180MG	TABLET;ORAL	Prescription

7. Drug name - ANGIOMAX

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7582727 (Pediatric)	SANDOZ INC	Pharmaceutical formulations of bivalirudin and processes of making the same	Jan, 2029 (6 years from now)
US7598343 (Pediatric)	SANDOZ INC	Pharmaceutical formulations of bivalirudin and processes of making the same	Jan, 2029 (6 years from now)

Drugs and Companies using BIVALIRUDIN ingredient

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS

Strength	Dosage	Availability
250MG/VIAL	INJECTABLE;INTRAVENOUS	Prescription

8. Drug name - ARNUITY ELLIPTA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8201556	GLAXOSMITHKLINE	Medicament dispenser	Feb, 2029 (6 years from now)

Drugs and Companies using FLUTICASONE FUROATE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.05MG/INH	POWDER;INHALATION	Prescription
0.1MG/INH	POWDER;INHALATION	Prescription
0.2MG/INH	POWDER;INHALATION	Prescription

9. Drug name - ATRIPLA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8598185	GILEAD SCIENCES	Unitary pharmaceutical dosage form	Apr, 2029 (6 years from now)

Drugs and Companies using EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
600MG;200MG;300MG	TABLET;ORAL	Prescription

10. Drug name - AUVI-Q

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8226610	KALEO INC	Medical injector with compliance tracking and monitoring	Apr, 2029 (6 years from now)
US8021344	KALEO INC	Medicament delivery device configured to produce an audible output	Nov, 2029 (7 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

Strength	Dosage	Availability
EQ 0.1MG/DELIVERY	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	Prescription
EQ 0.15MG/DELIVERY	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	Prescription
EQ 0.3MG/DELIVERY	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	Prescription

11. Drug name - BAXDELA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8871938	MELINTA	Process for making quinolone compounds	Sep, 2029 (6 years from now)
USRE46617	MELINTA	Process for making quinolone compounds	Dec, 2029 (7 years from now)
CN102164912A	MELINTA	Process For Preparing Quinolone Compounds	Sep, 2029 (6 years from now)
CN102164912B	MELINTA	Preparing Process Of Quinolones Compound	Sep, 2029 (6 years from now)
IN201101315P2	MELINTA	Process For Making Quinolone Compounds	Sep, 2029 (6 years from now)
IN290385B	MELINTA	Process For Making Quinolone Compounds	Sep, 2029 (6 years from now)
EP2346855A4	MELINTA	Process For Making Quinolone Compounds	Sep, 2029 (6 years from now)
EP2346855B1	MELINTA	Process For Making Quinolone Compounds	Sep, 2029 (6 years from now)
EP2346855A2	MELINTA	Process For Making Quinolone Compounds	Sep, 2029 (6 years from now)
EP3214083B1	MELINTA	Process For Making Quinolone Compounds	Sep, 2029 (6 years from now)
EP3214083A1	MELINTA	Process For Making Quinolone Compounds	Sep, 2029 (6 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9750822	MELINTA	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (6 years from now)
US8410077	MELINTA	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (6 years from now)
US9200088	MELINTA	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (6 years from now)
US7635773	MELINTA	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (6 years from now)

Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
EQ 300MG BASE/VIAL	POWDER;INTRAVENOUS	Prescription

12. Drug name - BELSOMRA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7951797	MERCK SHARP DOHME	Substituted diazepan orexin receptor antagonists	Nov, 2029 (7 years from now)

Drugs and Companies using SUVOREXANT ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
5MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription
15MG	TABLET;ORAL	Prescription
20MG	TABLET;ORAL	Prescription

13. Drug name - BESIVANCE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8937062	BAUSCH AND LOMB	Compositions and methods for treating, reducing, ameliorating, or preventing infections caused by antibacterial drug-resistant bacteria	Nov, 2029 (7 years from now)

Drugs and Companies using BESIFLOXACIN HYDROCHLORIDE ingredient

Treatment: Method of treating ocular bacterial infections

Dosage: SUSPENSION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
EQ 0.6% BASE	SUSPENSION/DROPS;OPHTHALMIC	Prescription

14. Drug name - BRAFTOVI

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8946250	ARRAY BIOPHARMA INC	3,4-diarylpyrazoles as protein kinase inhibitors	Jul, 2029 (6 years from now)
CN102105459B	ARRAY BIOPHARMA INC	3,4-Diarylpyrazoles As Protein Kinase Inhibitors	Jul, 2029 (6 years from now)
CN102105459A	ARRAY BIOPHARMA INC	3,4-Diarylpyrazoles As Protein Kinase Inhibitors	Jul, 2029 (6 years from now)
EP2324008A1	ARRAY BIOPHARMA INC	3,4-Diarylpyrazoles As Protein Kinase Inhibitors	Jul, 2029 (6 years from now)
EP2324008B1	ARRAY BIOPHARMA INC	3,4-Diarylpyrazoles As Protein Kinase Inhibitors	Jul, 2029 (6 years from now)

Drugs and Companies using ENCORAFENIB ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
50MG	CAPSULE;ORAL	Discontinued
75MG	CAPSULE;ORAL	Prescription

15. Drug name - BREO ELLIPTA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11116721	GLAXO GRP LTD	Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol	Feb, 2029 (6 years from now)

Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient

Treatment: Indicated for long-term, once-daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in pts with a history of exacerbations; indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.1MG/INH;EQ 0.025MG BASE/INH	POWDER;INHALATION	Prescription
0.2MG/INH;EQ 0.025MG BASE/INH	POWDER;INHALATION	Prescription

16. Drug name - BRISDELLE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8658663	SEBELA IRELAND LTD	Method of treating thermoregulatory disfunction with paroxetine	Apr, 2029 (6 years from now)

Drugs and Companies using PAROXETINE MESYLATE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 7.5MG BASE	CAPSULE;ORAL	Prescription

17. Drug name - BROMSITE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778999	SUN PHARM	Non-steroidal anti-inflammatory ophthalmic compositions	Aug, 2029 (6 years from now)

Drugs and Companies using BROMFENAC SODIUM ingredient

Treatment: Treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
EQ 0.075% ACID	SOLUTION/DROPS;OPHTHALMIC	Prescription

18. Drug name - BYDUREON

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8827963	ASTRAZENECA AB	Administering device with holding mechanism	Feb, 2029 (6 years from now)
US8690837	ASTRAZENECA AB	Mixing device for a two-chamber ampoule	May, 2029 (6 years from now)
US8827963 (Pediatric)	ASTRAZENECA AB	Administering device with holding mechanism	Aug, 2029 (6 years from now)
US8690837 (Pediatric)	ASTRAZENECA AB	Mixing device for a two-chamber ampoule	Nov, 2029 (7 years from now)

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

Strength	Dosage	Availability
2MG/VIAL	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	Discontinued
2MG	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	Discontinued

19. Drug name - CALDOLOR

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9138404	CUMBERLAND PHARMS	Treating critically ill patients with intravenous ibuprofen	Sep, 2029 (6 years from now)
US9295639	CUMBERLAND PHARMS	Treating critically ill patients with intravenous ibuprofen	Sep, 2029 (6 years from now)
US8871810	CUMBERLAND PHARMS	Treating critically ill patients with intravenous ibuprofen	Sep, 2029 (6 years from now)
US9649284	CUMBERLAND PHARMS	Treating critically ill patients with intravenous ibuprofen	Sep, 2029 (6 years from now)
US8735452	CUMBERLAND PHARMS	Treating patients with intravenous ibuprofen	Sep, 2029 (6 years from now)
US9114068	CUMBERLAND PHARMS	Treating patients with intravenous ibuprofen	Sep, 2029 (6 years from now)

Drugs and Companies using IBUPROFEN ingredient

Treatment: Methods of treating pain, inflammation and/or fever in a critically ill patient with intravenous ibuprofen in need thereof; Management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics, reduction in fever through anti-inflammatory, analgesic, and antipyretic activity; Management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics in a critically ill patient with intravenous ibuprofen in need thereof; Methods of treating pain, inflammation and/or fever with intravenous ibuprofen such that mean arterial blood pressure does not increase the dosage interval

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
400MG/4ML (100MG/ML)	SOLUTION;INTRAVENOUS	Discontinued
800MG/8ML (100MG/ML)	SOLUTION;INTRAVENOUS	Prescription
800MG/200ML (4MG/ML)	SOLUTION;INTRAVENOUS	Prescription

20. Drug name - CAPLYTA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE48825	INTRA-CELLULAR	4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms	Mar, 2029 (6 years from now)
US9586960	INTRA-CELLULAR	4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de] quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms	Mar, 2029 (6 years from now)
US8648077	INTRA-CELLULAR	4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals	Dec, 2029 (7 years from now)
CN102046175A	INTRA-CELLULAR	Substituted Heterocycle Fused Gamma-Carbolines Solid	Mar, 2029 (6 years from now)
CN102046175B	INTRA-CELLULAR	A Heterocyclic Ring Fused Gamma-Carbolines Solid	Mar, 2029 (6 years from now)
EP2262505B1	INTRA-CELLULAR	Substituted Heterocycle Fused Gamma-Carbolines Solid	Mar, 2029 (6 years from now)
EP2262505A2	INTRA-CELLULAR	Substituted Heterocycle Fused Gamma-Carbolines Solid	Mar, 2029 (6 years from now)
EP2262505A4	INTRA-CELLULAR	Substituted Heterocycle Fused Gamma-Carbolines Solid	Mar, 2029 (6 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9199995	INTRA-CELLULAR	4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals	Mar, 2029 (6 years from now)
US10117867	INTRA-CELLULAR	Methods and compositions for sleep disorders and other disorders	May, 2029 (6 years from now)
US9616061	INTRA-CELLULAR	Methods and compositions for sleep disorders and other disorders	May, 2029 (6 years from now)
USRE48839	INTRA-CELLULAR	Methods and compositions for sleep disorders and other disorders	Dec, 2029 (7 years from now)
US8598119	INTRA-CELLULAR	Methods and compositions for sleep disorders and other disorders	Dec, 2029 (7 years from now)

Drugs and Companies using LUMATEPERONE TOSYLATE ingredient

Treatment: Modulation of 5-hydroxytryptamine 2 receptor activity in schizophrenia; Treatment of bipolar depression; Treatment of bipolar depression; treatment of schizophrenia; Treatment of schizophrenia

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 42MG BASE	CAPSULE;ORAL	Prescription

21. Drug name - CARNEXIV

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7635773	LUNDBECK PHARMS LLC	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (6 years from now)
US8410077	LUNDBECK PHARMS LLC	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (6 years from now)
US9750822	LUNDBECK PHARMS LLC	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (6 years from now)

Drugs and Companies using CARBAMAZEPINE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
200MG/20ML (10MG/ML)	SOLUTION;INTRAVENOUS	Discontinued

22. Drug name - COLCRYS

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7601758	TAKEDA PHARMS USA	Methods for concomitant administration of colchicine and macrolide antibiotics in the treatment of gout flares	Feb, 2029 (6 years from now)
US8440721	TAKEDA PHARMS USA	Methods for concomitant administration of colchicine and a second active agent	Feb, 2029 (6 years from now)
US8440722	TAKEDA PHARMS USA	Methods for concomitant administration of colchicine and a second active agent	Feb, 2029 (6 years from now)
US7906519	TAKEDA PHARMS USA	Methods for concomitant administration of colchicine and a second active agent	Feb, 2029 (6 years from now)
US7820681	TAKEDA PHARMS USA	Methods for concomitant administration of colchicine and a second active agent	Feb, 2029 (6 years from now)
US7915269	TAKEDA PHARMS USA	Methods for concomitant administration of colchicine and a second active agent	Feb, 2029 (6 years from now)

Drugs and Companies using COLCHICINE ingredient

Treatment: Method of treating gout flares; Method of using colchicine for the prophylaxis of gout flares; Method of administering colchicine to familial mediterranean fever patients

Dosage: TABLET;ORAL

Strength	Dosage	Availability
0.6MG	TABLET;ORAL	Prescription

23. Drug name - CONSENSI

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9662315	PURPLE BIOTECH	Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs	May, 2029 (6 years from now)

Drugs and Companies using AMLODIPINE BESYLATE; CELECOXIB ingredient

Treatment: Treatment of adult patients for whom treatment with both amlodipine for hypertension and celecoxib for osteoarthritis are appropriate

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 2.5MG BASE;200MG	TABLET;ORAL	Discontinued
EQ 5MG BASE;200MG	TABLET;ORAL	Discontinued
EQ 10MG BASE;200MG	TABLET;ORAL	Discontinued

24. Drug name - CONTRAVE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8088786	NALPROPION	Layered pharmaceutical formulations	Feb, 2029 (6 years from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
90MG;8MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

25. Drug name - COPIKTRA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216982	SECURA	Certain chemical entities, compositions and methods	Jan, 2029 (6 years from now)

Drugs and Companies using DUVELISIB ingredient

Treatment: For the treatment of patients with follicular lymphoma (fl); for the treatment of patients with chronic lymphocytic leukemia (cll) and/or small lymphocytic leukemia (sll)

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
15MG	CAPSULE;ORAL	Prescription
25MG	CAPSULE;ORAL	Prescription

26. Drug name - COTELLIC

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7803839	GENENTECH INC	Azetidines as MEK inhibitors for the treatment of proliferative diseases	Nov, 2029 (7 years from now)

Drugs and Companies using COBIMETINIB FUMARATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 20MG BASE	TABLET;ORAL	Prescription

27. Drug name - DAKLINZA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8329159	BRISTOL-MYERS SQUIBB	Hepatitis C virus inhibitors	Jul, 2029 (6 years from now)
EP2049522A2	BRISTOL-MYERS SQUIBB	Hepatitis C Virus Inhibitors	Aug, 2029 (6 years from now)
EP2049522B1	BRISTOL-MYERS SQUIBB	Hepatitis C Virus Inhibitors	Aug, 2029 (6 years from now)

Drugs and Companies using DACLATASVIR DIHYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 30MG BASE	TABLET;ORAL	Discontinued
EQ 60MG BASE	TABLET;ORAL	Discontinued
EQ 90MG BASE	TABLET;ORAL	Discontinued

28. Drug name - DESYREL

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8133893	PRAGMA	Trazodone and trazodone hydrochloride in purified form	Mar, 2029 (6 years from now)

Drugs and Companies using TRAZODONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
50MG	TABLET;ORAL	Discontinued
100MG	TABLET;ORAL	Discontinued
150MG	TABLET;ORAL	Discontinued
300MG	TABLET;ORAL	Discontinued

29. Drug name - DEXILANT SOLUTAB

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9241910	TAKEDA PHARMS USA	Orally-disintegrating solid preparation	Mar, 2029 (6 years from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

Strength	Dosage	Availability
30MG	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL	Discontinued

30. Drug name - DOVATO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9242986	VIIV HLTHCARE	Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates	Dec, 2029 (7 years from now)
CN102245182B	VIIV HLTHCARE	Carbamoyl Pyridone Hiv Integrase Inhibitors And Intermediates For Synthesis	Dec, 2029 (7 years from now)
CN102245182A	VIIV HLTHCARE	Synthesis Of Carbamoyl Pyridone Hiv Integrase Inhibitors And Intermediate	Dec, 2029 (7 years from now)
IN373756B	VIIV HLTHCARE	Process For The Preparation Of Carbamoylpyrid One Hiv Integrase Inhibitors	Dec, 2029 (7 years from now)
IN201838011858A	VIIV HLTHCARE	Process For The Preparation Of Carbamoylpyridone Hiv Integrase Inhibitors	Dec, 2029 (7 years from now)
EP2376080A4	VIIV HLTHCARE	Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates	Dec, 2029 (7 years from now)
EP2376080B1	VIIV HLTHCARE	Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates	Dec, 2029 (7 years from now)
EP2376080A1	VIIV HLTHCARE	Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates	Dec, 2029 (7 years from now)

Drugs and Companies using DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 50MG BASE;300MG	TABLET;ORAL	Prescription

31. Drug name - DUAKLIR PRESSAIR

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11000517	ASTRAZENECA	Dosage and formulation	Mar, 2029 (6 years from now)
US10085974	ASTRAZENECA	Dosage and formulation	Mar, 2029 (6 years from now)

Drugs and Companies using ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE ingredient

Treatment: Maintenance treatment of chronic obstructive pulmonary disease (copd)

Dosage: POWDER, METERED;INHALATION

Strength	Dosage	Availability
0.4MG/INH;0.012MG/INH	POWDER, METERED;INHALATION	Prescription

32. Drug name - DURYSTA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7799336	ALLERGAN INC	Hypotensive lipid-containing biodegradable intraocular implants and related methods	Apr, 2029 (6 years from now)

Drugs and Companies using BIMATOPROST ingredient

Treatment: NA

Dosage: IMPLANT;OPHTHALMIC

Strength	Dosage	Availability
10MCG	IMPLANT;OPHTHALMIC	Prescription

33. Drug name - DUTREBIS

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7754731	MERCK SHARP DOHME	Potassium salt of an HIV integrase inhibitor	Mar, 2029 (6 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7754731 (Pediatric)	MERCK SHARP DOHME	Potassium salt of an HIV integrase inhibitor	Sep, 2029 (6 years from now)

Drugs and Companies using LAMIVUDINE; RALTEGRAVIR POTASSIUM ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
150MG;EQ 300MG BASE	TABLET;ORAL	Discontinued

34. Drug name - DUZALLO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8546437	IRONWOOD PHARMS INC	Compounds and compositions and methods of use	Apr, 2029 (6 years from now)
US8084483	IRONWOOD PHARMS INC	Compounds and compositions and methods of use	Aug, 2029 (6 years from now)

Drugs and Companies using ALLOPURINOL; LESINURAD ingredient

Treatment: Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone

Dosage: TABLET;ORAL

Strength	Dosage	Availability
200MG;200MG	TABLET;ORAL	Discontinued
300MG;200MG	TABLET;ORAL	Discontinued

35. Drug name - DYANAVEL XR

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8062667	TRIS PHARMA INC	Modified release formulations containing drug-ion exchange resin complexes	Mar, 2029 (6 years from now)

Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
2MG/ML;EQ 0.5MG BASE/ML	SUSPENSION, EXTENDED RELEASE;ORAL	Prescription

36. Drug name - ELLA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735380	LAB HRA PHARMA	Ulipristal acetate tablets	Feb, 2029 (6 years from now)

Drugs and Companies using ULIPRISTAL ACETATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
30MG	TABLET;ORAL	Prescription

37. Drug name - EMBEDA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8623418	ALPHARMA PHARMS	Pharmaceutical composition	Nov, 2029 (7 years from now)

Drugs and Companies using MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE ingredient

Treatment: Treatment of moderate to severe chronic pain by administering an intact composition as claimed

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
20MG;0.8MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
30MG;1.2MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
50MG;2MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
60MG;2.4MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
80MG;3.2MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
100MG;4MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued

38. Drug name - EPCLUSA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7964580	GILEAD SCIENCES INC	NA	Mar, 2029 (6 years from now)
US8633309	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Mar, 2029 (6 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8889159	GILEAD SCIENCES INC	Compositions and methods for treating hepatitis C virus	Mar, 2029 (6 years from now)
US7964580 (Pediatric)	GILEAD SCIENCES INC	NA	Sep, 2029 (6 years from now)
US8633309 (Pediatric)	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Sep, 2029 (6 years from now)
US8889159 (Pediatric)	GILEAD SCIENCES INC	Compositions and methods for treating hepatitis C virus	Sep, 2029 (6 years from now)

Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient

Treatment: For the treatment of hepatitis c

Dosage: TABLET;ORAL

Strength	Dosage	Availability
200MG;50MG	TABLET;ORAL	Prescription
400MG;100MG	TABLET;ORAL	Prescription

39. Drug name - ESBRIET

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7635707	GENENTECH INC	Pirfenidone treatment for patients with atypical liver function	Apr, 2029 (6 years from now)
US8609701	GENENTECH INC	Pirfenidone treatment for patients with atypical liver function	Apr, 2029 (6 years from now)
US8592462	GENENTECH INC	Pirfenidone treatment for patients with atypical liver function	Apr, 2029 (6 years from now)
US7566729	GENENTECH INC	Modifying pirfenidone treatment for patients with atypical liver function	Apr, 2029 (6 years from now)

Drugs and Companies using PIRFENIDONE ingredient

Treatment: Continued dosing or dosage modification following elevated liver enzymes in treatment of idiopathic pulmonary fibrosis; Continued dosing or dosage modification following elvated liver enzymes in use of pirfenidone; Dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by discontinuing pirfenidone until biomarkers of liver function are within normal limits, then at least 1600mg/day in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by discontinuing pirfenidone until biomarkers are within normal limits, followed by administering at least 1600 mg/day in treatment of ipf; dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by administering sub-1600 mg/day, following by administering at least 1600 mg/day in treatment of ipf; dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by administering sub-2400mg/day dose, followed by administering 2403mg/day in treatment of ipf; dosing 2403 mg/day pirfenidone following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by administering sub-1600 mg/day dose, followed by administering at least 1600 mg/day dose in treatment of ipf; dosing of at least 1600 mg/day following grade 2 liver abnormality in biomarker ast and/or alt after pirfenidone administration in treatment of ipf; dosing of at least 1600 mg/day following grade 2 abnormality in liver function biomarker after pirfenidone administration in treatment of ipf; dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by discontinuing pirfenidone until biomarkers of liver function are within normal limits, followed by full daily dose in treatment of ipf; Dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by discontinuing pirfenidone until biomarkers are within limits, then sub-2400mg/day dose, then full daily dose in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by administering sub-2400mg/day dose then full daily dose in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by administering sub-2400 mg/day dose then full day daily dose in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by discontinuing pirfenidone until biomarkers are within normal limits, then sub-2400mg/day dose, then full daily dose in treatment of ipf

Dosage: TABLET;ORAL

Strength	Dosage	Availability
267MG	TABLET;ORAL	Prescription
534MG	TABLET;ORAL	Discontinued
801MG	TABLET;ORAL	Prescription

40. Drug name - EUCRISA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8039451	ANACOR PHARMS INC	Boron-containing small molecules	Jun, 2029 (6 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8039451 (Pediatric)	ANACOR PHARMS INC	Boron-containing small molecules	Dec, 2029 (7 years from now)

Drugs and Companies using CRISABOROLE ingredient

Treatment: NA

Dosage: OINTMENT;TOPICAL

Strength	Dosage	Availability
2%	OINTMENT;TOPICAL	Prescription

41. Drug name - EVOMELA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410077	ACROTECH	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (6 years from now)
US9200088	ACROTECH	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (6 years from now)

Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
EQ 50MG BASE/VIAL	POWDER;INTRAVENOUS	Prescription

42. Drug name - EVOTAZ

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8148374	BRISTOL-MYERS SQUIBB	Modulators of pharmacokinetic properties of therapeutics	Sep, 2029 (6 years from now)

Drugs and Companies using ATAZANAVIR SULFATE; COBICISTAT ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 300MG BASE;150MG	TABLET;ORAL	Prescription

43. Drug name - EVZIO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8226610	KALEO INC	Medical injector with compliance tracking and monitoring	Apr, 2029 (6 years from now)
US8021344	KALEO INC	Medicament delivery device configured to produce an audible output	Nov, 2029 (7 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

Strength	Dosage	Availability
0.4MG/0.4ML (0.4MG/0.4ML)	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	Discontinued

44. Drug name - EVZIO (AUTOINJECTOR)

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8226610	KALEO INC	Medical injector with compliance tracking and monitoring	Apr, 2029 (6 years from now)
US8021344	KALEO INC	Medicament delivery device configured to produce an audible output	Nov, 2029 (7 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

Strength	Dosage	Availability
2MG/0.4ML (2MG/0.4ML)	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	Discontinued

45. Drug name - EXONDYS 51

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47769	SAREPTA THERAPS INC	Antisense oligonucleotides for inducing exon skipping and methods of use thereof	Feb, 2029 (6 years from now)

Drugs and Companies using ETEPLIRSEN ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
100MG/2ML (50MG/ML)	SOLUTION;INTRAVENOUS	Prescription
500MG/10ML (50MG/ML)	SOLUTION;INTRAVENOUS	Prescription

46. Drug name - FARXIGA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7919598	ASTRAZENECA AB	Crystal structures of SGLT2 inhibitors and processes for preparing same	Dec, 2029 (7 years from now)

Drugs and Companies using DAPAGLIFLOZIN ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
5MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription

47. Drug name - FERRIPROX

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8703156	CHIESI	Liquid formulation for deferiprone with palatable taste	Oct, 2029 (7 years from now)

Drugs and Companies using DEFERIPRONE ingredient

Treatment: Method of treating transfusional iron overload

Dosage: SOLUTION;ORAL

Strength	Dosage	Availability
80MG/ML	SOLUTION;ORAL	Discontinued
100MG/ML	SOLUTION;ORAL	Prescription

48. Drug name - FINACEA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9211259	LEO PHARMA AS	Antibiotic kit and composition and uses thereof	Feb, 2029 (6 years from now)

Drugs and Companies using AZELAIC ACID ingredient

Treatment: Topical treatment of inflammatory papules and pustules of mild to moderate rosacea

Dosage: AEROSOL, FOAM;TOPICAL

Strength	Dosage	Availability
15%	AEROSOL, FOAM;TOPICAL	Prescription

49. Drug name - FIRMAGON

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10729739	FERRING	Methods of treating prostate cancer with GnRH antagonist	Feb, 2029 (6 years from now)
US10973870	FERRING	Methods of treating prostate cancer with GnRH antagonist	Feb, 2029 (6 years from now)
US9579359	FERRING	Method of treating prostate cancer with GnRH antagonist	Feb, 2029 (6 years from now)

Drugs and Companies using DEGARELIX ACETATE ingredient

Treatment: Treatment of advanced prostate cancer with a reduced likelihood of causing a gonadotrophin releasing hormone agonist side-effect

Dosage: POWDER;SUBCUTANEOUS

Strength	Dosage	Availability
EQ 80MG BASE/VIAL	POWDER;SUBCUTANEOUS	Prescription
EQ 120MG BASE/VIAL	POWDER;SUBCUTANEOUS	Prescription

50. Drug name - FYARRO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8911786	AADI	Nanoparticle comprising rapamycin and albumin as anticancer agent	Feb, 2029 (6 years from now)

Drugs and Companies using SIROLIMUS ingredient

Treatment: Treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (pecoma)

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
100MG/VIAL	POWDER;INTRAVENOUS	Prescription

51. Drug name - GALAFOLD

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8592362	AMICUS THERAP US	Method to predict response to pharmacological chaperone treatment of diseases	Feb, 2029 (6 years from now)
US10813921	AMICUS THERAP US	Method to predict response to pharmacological chaperone treatment of diseases	Feb, 2029 (6 years from now)
USRE48608	AMICUS THERAP US	Method to predict response to pharmacological chaperone treatment of diseases	Feb, 2029 (6 years from now)
US9095584	AMICUS THERAP US	Method to predict response to pharmacological chaperone treatment of diseases	Feb, 2029 (6 years from now)

Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient

Treatment: The treatment of fabry patients

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 123MG BASE	CAPSULE;ORAL	Prescription

52. Drug name - GELNIQUE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9259388	ALLERGAN	Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions	Nov, 2029 (7 years from now)
US10449173	ALLERGAN	Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions	Nov, 2029 (7 years from now)

Drugs and Companies using OXYBUTYNIN CHLORIDE ingredient

Treatment: Treatment of overactive bladder by application of oxybutynin chloride gel to skin; Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence with a single unit dose of 10% oxybutynin chloride gel

Dosage: GEL;TRANSDERMAL

Strength	Dosage	Availability
10% (100MG/PACKET)	GEL;TRANSDERMAL	Prescription

53. Drug name - GEMTESA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8653260	UROVANT	Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists	Apr, 2029 (6 years from now)
CN102056917A	UROVANT	Hydroxymethyl Pyrrolidines As [Beta]3 Adrenergic Receptor Agonists	Apr, 2029 (6 years from now)
CN102391255B	UROVANT	Hydroxymethyl Pyrrolidine As 3 Adrenergic Receptor Agonists	Apr, 2029 (6 years from now)
CN102391255A	UROVANT	Hydroxymethyl Pyrrolidines As Beta 3 Adrenergic Receptor Agonist	Apr, 2029 (6 years from now)
CN102056917B	UROVANT	Hydroxymethyl Pyrrolidine As 3 Adrenergic Receptor Agonists	Apr, 2029 (6 years from now)
EP2276756B1	UROVANT	Hydroxymethyl Pyrrolidines As Beta 3 Adrenergic Receptor Agonists	Apr, 2029 (6 years from now)
EP2276756A1	UROVANT	Hydroxymethyl Pyrrolidines As Beta 3 Adrenergic Receptor Agonists	Apr, 2029 (6 years from now)
EP2276756B8	UROVANT	Hydroxymethyl Pyrrolidines As Beta 3 Adrenergic Receptor Agonists	Apr, 2029 (6 years from now)
EP2276756B9	UROVANT	Hydroxymethyl Pyrrolidines As Beta 3 Adrenergic Receptor Agonists	Apr, 2029 (6 years from now)

Drugs and Companies using VIBEGRON ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
75MG	TABLET;ORAL	Prescription

54. Drug name - GENOSYL

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9701538	VERO BIOTECH	Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)	Jan, 2029 (6 years from now)
US8944049	VERO BIOTECH	Systems and devices for generating nitric oxide	Aug, 2029 (6 years from now)
US9604028	VERO BIOTECH	Systems and devices for generating nitric oxide	Aug, 2029 (6 years from now)
US10926054	VERO BIOTECH	Systems and devices for generating nitric oxide	Aug, 2029 (6 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Treatment: A method for delivering nitric oxide to a patient with pulmonary hypertension or hypoxia

Dosage: GAS;INHALATION

Strength	Dosage	Availability
800PPM	GAS;INHALATION	Prescription

55. Drug name - GENVOYA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8148374	GILEAD SCIENCES INC	Modulators of pharmacokinetic properties of therapeutics	Sep, 2029 (6 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9891239	GILEAD SCIENCES INC	Modulators of pharmacokinetic properties of therapeutics	Sep, 2029 (6 years from now)

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

Strength	Dosage	Availability
150MG;150MG;200MG;EQ 10MG BASE	TABLET;ORAL	Prescription

56. Drug name - GIAPREZA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9867863	LA JOLLA PHARMA	Method of treating low blood pressure	Dec, 2029 (7 years from now)
US10335451	LA JOLLA PHARMA	Method of treating low blood pressure	Dec, 2029 (7 years from now)
US10548943	LA JOLLA PHARMA	Method of treating low blood pressure	Dec, 2029 (7 years from now)
US10500247	LA JOLLA PHARMA	Method of treating low blood pressure	Dec, 2029 (7 years from now)

Drugs and Companies using ANGIOTENSIN II ACETATE ingredient

Treatment: Treating refractory hypotension with about 5 ng/kg/min to about 20 ng/kg/min angiotensin ii in a patient receiving vasopressor; Treating hypotension with about 20 ng/kg/min to about 40 ng/kg/min angiotensin ii in a human subject having septic shock; Increasing blood pressure with a rate of about 20 ng/kg/min to about 40 ng/kg/min angiotensin ii in a human subject having septic shock; increasing blood pressure with an initial rate of about 20 ng/kg/min angiotensin ii in a human subject having septic shock, and titrating the rate up.; Treating low blood pressure with angiotensin ii with an initial rate of about 5 ng/kg/min to about 20 ng/kg/min in a subject having refractory hypotension or severe hypotension, and titrating the rate up; treating low blood pressure with angiotensin ii with an initial rate of about 5 ng/kg/min to about 20 ng/kg/min in a subject having refractory hypotension or severe hypotension

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
EQ 0.5MG BASE/ML (EQ 0.5MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription
EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription
EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)	SOLUTION;INTRAVENOUS	Discontinued

57. Drug name - GILOTRIF

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8426586	BOEHRINGER INGELHEIM	Process for preparing amino crotonyl compounds	Oct, 2029 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8545884	BOEHRINGER INGELHEIM	Solid pharmaceutical formulations comprising BIBW 2992	Dec, 2029 (7 years from now)

Drugs and Companies using AFATINIB DIMALEATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 20MG BASE	TABLET;ORAL	Prescription
EQ 30MG BASE	TABLET;ORAL	Prescription
EQ 40MG BASE	TABLET;ORAL	Prescription

58. Drug name - GIMOTI

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020361	EVOKE PHARMA INC	Nasal formulations of metoclopramide	Dec, 2029 (7 years from now)

Drugs and Companies using METOCLOPRAMIDE HYDROCHLORIDE ingredient

Treatment: Nasal administration of metoclopramide for treatment of diabetic gastroparesis

Dosage: SPRAY, METERED;NASAL

Strength	Dosage	Availability
EQ 15MG BASE/SPRAY	SPRAY, METERED;NASAL	Prescription

59. Drug name - GIVLAARI

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8106022	ALNYLAM PHARMS INC	Carbohydrate conjugates as delivery agents for oligonucleotides	Dec, 2029 (7 years from now)

Drugs and Companies using GIVOSIRAN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
EQ 189MG BASE/ML (EQ 189MG BASE/ML)	SOLUTION;SUBCUTANEOUS	Prescription

60. Drug name - GLYXAMBI

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8551957	BOEHRINGER INGELHEIM	Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate	Oct, 2029 (7 years from now)

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin

Dosage: TABLET;ORAL

Strength	Dosage	Availability
10MG;5MG	TABLET;ORAL	Prescription
25MG;5MG	TABLET;ORAL	Prescription

61. Drug name - HARVONI

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7964580	GILEAD SCIENCES INC	NA	Mar, 2029 (6 years from now)
US8633309	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Mar, 2029 (6 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8889159	GILEAD SCIENCES INC	Compositions and methods for treating hepatitis C virus	Mar, 2029 (6 years from now)
US7964580 (Pediatric)	GILEAD SCIENCES INC	NA	Sep, 2029 (6 years from now)
US8633309 (Pediatric)	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Sep, 2029 (6 years from now)
US8889159 (Pediatric)	GILEAD SCIENCES INC	Compositions and methods for treating hepatitis C virus	Sep, 2029 (6 years from now)

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

Treatment: For the treatment of hepatitis c

Dosage: PELLETS;ORAL

Strength	Dosage	Availability
33.75MG;150MG/PACKET	PELLETS;ORAL	Prescription
45MG;200MG/PACKET	PELLETS;ORAL	Prescription

62. Drug name - HORIZANT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8795725	ARBOR PHARMS LLC	GABA analog prodrug sustained release oral dosage forms	Jun, 2029 (6 years from now)

Drugs and Companies using GABAPENTIN ENACARBIL ingredient

Treatment: Treatment of moderate-to-severe primary restless leg syndrome in adults; management of postherpetic neuralgia (phn) in adults

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
300MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
600MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

63. Drug name - IBSRELA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8541448	ARDELYX INC	Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders	Dec, 2029 (7 years from now)
US8969377	ARDELYX INC	Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders	Dec, 2029 (7 years from now)
CN103819403A	ARDELYX INC	Compounds And Methods For Inhibiting Nhe-Mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders	Dec, 2029 (7 years from now)
CN103819403B	ARDELYX INC	Compounds And Methods For Inhibiting Nhe-Mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders	Dec, 2029 (7 years from now)
IN329133B	ARDELYX INC	Compounds And Methods For Inhibiting Nhemediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders	Dec, 2029 (7 years from now)
IN201105002P4	ARDELYX INC	Compounds And Methods For Inhibiting Sodium Hydrogen Exchanger-Mediated Antiport In Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders	Dec, 2029 (7 years from now)
EP2384318A2	ARDELYX INC	Compounds And Methods For Inhibiting Nhe-Mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders	Dec, 2029 (7 years from now)
EP3351248A1	ARDELYX INC	Compounds And Methods For Inhibiting Nhe-Mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders	Dec, 2029 (7 years from now)
EP3351248B1	ARDELYX INC	Compounds And Methods For Inhibiting Nhe-Mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders	Dec, 2029 (7 years from now)
EP2384318B1	ARDELYX INC	Compounds And Methods For Inhibiting Nhe-Mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders	Dec, 2029 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9408840	ARDELYX INC	Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder	Dec, 2029 (7 years from now)

Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient

Treatment: Method of treating irritable bowel syndrome with constipation by administering tenapanor

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 50MG BASE	TABLET;ORAL	Prescription

64. Drug name - INBRIJA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE43711	ACORDA	Pulmonary delivery for levodopa	Feb, 2029 (6 years from now)

Drugs and Companies using LEVODOPA ingredient

Treatment: Intermittent treatment of off episodes in patients with parkinson's disease treated with carbidopa/levodopa by inhalation of levodopa powder particles

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
42MG	POWDER;INHALATION	Prescription

65. Drug name - INCRUSE ELLIPTA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8201556	GLAXO GRP ENGLAND	Medicament dispenser	Feb, 2029 (6 years from now)

Drugs and Companies using UMECLIDINIUM BROMIDE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
EQ 62.5MCG BASE/INH	POWDER;INHALATION	Prescription

66. Drug name - INGREZZA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8039627	NEUROCRINE	Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto	Oct, 2029 (7 years from now)

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 40MG BASE	CAPSULE;ORAL	Prescription
EQ 60MG BASE	CAPSULE;ORAL	Prescription
EQ 80MG BASE	CAPSULE;ORAL	Prescription

67. Drug name - INOMAX

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431163	MALLINCKRODT HOSP	Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas	Jun, 2029 (6 years from now)
US8282966	MALLINCKRODT HOSP	Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide	Jun, 2029 (6 years from now)
US8795741	MALLINCKRODT HOSP	Methods for treating patients who are candidates for inhaled nitric oxide treatment	Jun, 2029 (6 years from now)
US8846112	MALLINCKRODT HOSP	Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation	Jun, 2029 (6 years from now)
US8293284	MALLINCKRODT HOSP	Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide	Jun, 2029 (6 years from now)
US8846112 (Pediatric)	MALLINCKRODT HOSP	Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation	Dec, 2029 (7 years from now)
US8282966 (Pediatric)	MALLINCKRODT HOSP	Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide	Dec, 2029 (7 years from now)
US8795741 (Pediatric)	MALLINCKRODT HOSP	Methods for treating patients who are candidates for inhaled nitric oxide treatment	Dec, 2029 (7 years from now)
US8431163 (Pediatric)	MALLINCKRODT HOSP	Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas	Dec, 2029 (7 years from now)
US8293284 (Pediatric)	MALLINCKRODT HOSP	Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide	Dec, 2029 (7 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Treatment: A method of reducing the risk of pulmonary edema in patients in need of treatment with inhaled nitric oxide

Dosage: GAS;INHALATION

Strength	Dosage	Availability
100PPM	GAS;INHALATION	Discontinued
800PPM	GAS;INHALATION	Prescription

68. Drug name - INTERMEZZO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8242131	PURDUE PHARMA	Methods of treating middle-of-the-night insomnia	Aug, 2029 (6 years from now)

Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Treatment: Method of treating middle-of-the-night insomnia

Dosage: TABLET;SUBLINGUAL

Strength	Dosage	Availability
1.75MG	TABLET;SUBLINGUAL	Discontinued
3.5MG	TABLET;SUBLINGUAL	Discontinued

69. Drug name - INVOKAMET

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7943582	JANSSEN PHARMS	Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate	Feb, 2029 (6 years from now)

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
50MG;500MG	TABLET;ORAL	Prescription
50MG;1GM	TABLET;ORAL	Prescription
150MG;500MG	TABLET;ORAL	Prescription
150MG;1GM	TABLET;ORAL	Prescription

70. Drug name - INVOKAMET XR

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7943582	JANSSEN PHARMS	Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate	Feb, 2029 (6 years from now)

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
50MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
50MG;500MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
150MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
150MG;500MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

71. Drug name - INVOKANA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7943582	JANSSEN PHARMS	Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate	Feb, 2029 (6 years from now)

Drugs and Companies using CANAGLIFLOZIN ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
100MG	TABLET;ORAL	Prescription
300MG	TABLET;ORAL	Prescription

72. Drug name - ISENTRESS

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7754731	MERCK SHARP DOHME	Potassium salt of an HIV integrase inhibitor	Mar, 2029 (6 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7754731 (Pediatric)	MERCK SHARP DOHME	Potassium salt of an HIV integrase inhibitor	Sep, 2029 (6 years from now)

Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 400MG BASE	TABLET;ORAL	Prescription
EQ 600MG BASE	TABLET;ORAL	Prescription

73. Drug name - ISTURISA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8314097	RECORDATI RARE	Organic compounds	Mar, 2029 (6 years from now)

Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 1MG BASE	TABLET;ORAL	Prescription
EQ 5MG BASE	TABLET;ORAL	Prescription
EQ 10MG BASE	TABLET;ORAL	Prescription

74. Drug name - IZBA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9144561	NOVARTIS	Pharmaceutical compositions having desirable bioavailability	Mar, 2029 (6 years from now)
US8754123	NOVARTIS	Pharmaceutical compositions having desirable bioavailability	May, 2029 (6 years from now)
US8722735	NOVARTIS	Pharmaceutical compositions having desirable bioavailability	Oct, 2029 (7 years from now)
US8178582	NOVARTIS	Pharmaceutical compositions having desirable bioavailability	Oct, 2029 (7 years from now)

Drugs and Companies using TRAVOPROST ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
0.003%	SOLUTION/DROPS;OPHTHALMIC	Discontinued

75. Drug name - JANUMET

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8414921 (Pediatric)	MERCK SHARP DOHME	Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin	Jan, 2029 (6 years from now)

Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
1GM;EQ 50MG BASE	TABLET;ORAL	Prescription
500MG;EQ 50MG BASE	TABLET;ORAL	Prescription

76. Drug name - JARDIANCE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8551957	BOEHRINGER INGELHEIM	Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate	Oct, 2029 (7 years from now)

Drugs and Companies using EMPAGLIFLOZIN ingredient

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin

Dosage: TABLET;ORAL

Strength	Dosage	Availability
10MG	TABLET;ORAL	Prescription
25MG	TABLET;ORAL	Prescription

77. Drug name - JATENZO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8241664	CLARUS	Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same	Mar, 2029 (6 years from now)

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Treatment: Method of treating testosterone deficiency

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
158MG	CAPSULE;ORAL	Prescription
198MG	CAPSULE;ORAL	Prescription
237MG	CAPSULE;ORAL	Prescription

78. Drug name - JENTADUETO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9415016	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Apr, 2029 (6 years from now)
US10973827	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Apr, 2029 (6 years from now)
US10022379	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Apr, 2029 (6 years from now)

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Use of a pharmaceutical composition comprising linagliptin, metformin and a basic amino acid to treat type 2 diabetes mellitus

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2.5MG;1GM	TABLET;ORAL	Prescription
2.5MG;500MG	TABLET;ORAL	Prescription
2.5MG;850MG	TABLET;ORAL	Prescription

79. Drug name - JENTADUETO XR

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10022379	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Apr, 2029 (6 years from now)
US9415016	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Apr, 2029 (6 years from now)

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Use of a pharmaceutical composition comprising linagliptin, metformin and a basic amino acid to treat type 2 diabetes mellitus

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
2.5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription

80. Drug name - JULUCA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9242986	VIIV HLTHCARE	Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates	Dec, 2029 (7 years from now)
CN102245182B	VIIV HLTHCARE	Carbamoyl Pyridone Hiv Integrase Inhibitors And Intermediates For Synthesis	Dec, 2029 (7 years from now)
CN102245182A	VIIV HLTHCARE	Synthesis Of Carbamoyl Pyridone Hiv Integrase Inhibitors And Intermediate	Dec, 2029 (7 years from now)
IN373756B	VIIV HLTHCARE	Process For The Preparation Of Carbamoylpyrid One Hiv Integrase Inhibitors	Dec, 2029 (7 years from now)
IN201838011858A	VIIV HLTHCARE	Process For The Preparation Of Carbamoylpyridone Hiv Integrase Inhibitors	Dec, 2029 (7 years from now)
EP2376080A4	VIIV HLTHCARE	Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates	Dec, 2029 (7 years from now)
EP2376080B1	VIIV HLTHCARE	Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates	Dec, 2029 (7 years from now)
EP2376080A1	VIIV HLTHCARE	Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates	Dec, 2029 (7 years from now)

Drugs and Companies using DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 50MG BASE;EQ 25MG BASE	TABLET;ORAL	Prescription

81. Drug name - KALYDECO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10646481	VERTEX PHARMS	Pharmaceutical composition and administrations thereof	Aug, 2029 (6 years from now)

Drugs and Companies using IVACAFTOR ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
150MG	TABLET;ORAL	Prescription

82. Drug name - KALYDECO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10646481	VERTEX PHARMS INC	Pharmaceutical composition and administrations thereof	Aug, 2029 (6 years from now)

Drugs and Companies using IVACAFTOR ingredient

Treatment: NA

Dosage: GRANULE;ORAL

Strength	Dosage	Availability
25MG/PACKET	GRANULE;ORAL	Prescription
50MG/PACKET	GRANULE;ORAL	Prescription
75MG/PACKET	GRANULE;ORAL	Prescription

83. Drug name - KARBINAL ER

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8062667	AYTU	Modified release formulations containing drug-ion exchange resin complexes	Mar, 2029 (6 years from now)

Drugs and Companies using CARBINOXAMINE MALEATE ingredient

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
4MG/5ML	SUSPENSION, EXTENDED RELEASE;ORAL	Prescription

84. Drug name - KAZANO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8900638	TAKEDA PHARMS USA	Solid preparation comprising alogliptin and metformin hydrochloride	May, 2029 (6 years from now)

Drugs and Companies using ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 12.5MG BASE;1GM	TABLET;ORAL	Prescription
EQ 12.5MG BASE;500MG	TABLET;ORAL	Prescription

85. Drug name - KENGREAL

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9925265	CHIESI	Methods of treating or preventing stent thrombosis	May, 2029 (6 years from now)

Drugs and Companies using CANGRELOR ingredient

Treatment: Method of reducing the risk of periprocedural myocardial infarction, and stent thrombosis in a patient undergoing pci by administering intravenously 30 ug/kg bolus before pci and then a continuous infusion

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
50MG/VIAL	POWDER;INTRAVENOUS	Prescription

86. Drug name - KERENDIA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8436180	BAYER HLTHCARE	Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof	Apr, 2029 (6 years from now)

Drugs and Companies using FINERENONE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
10MG	TABLET;ORAL	Prescription
20MG	TABLET;ORAL	Prescription

87. Drug name - KIMYRSA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420592	MELINTA THERAP	Methods of treatment using single doses of oritavancin	Aug, 2029 (6 years from now)

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

Treatment: Treatment of acute bacterial skin and skin structure infections with a single dose of 1200mg oritavancin or its single dose equivalent

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
EQ 1.2GM BASE/VIAL	POWDER;INTRAVENOUS	Prescription

88. Drug name - KISQALI

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8415355	NOVARTIS	Pyrrolopyrimidine compounds and their uses	Aug, 2029 (6 years from now)
CN102186856B	NOVARTIS	Pyrrolopyrimidine Compounds As Cdk Inhibitors	Aug, 2029 (6 years from now)
CN102186856A	NOVARTIS	Pyrrolopyrimidine Compounds As Cdk Inhibitors	Aug, 2029 (6 years from now)
EP2331547B1	NOVARTIS	Pyrrolopyrimidine Compounds As Cdk Inhibitors	Aug, 2029 (6 years from now)
EP2331547A1	NOVARTIS	Pyrrolopyrimidine Compounds As Cdk Inhibitors	Aug, 2029 (6 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9416136	NOVARTIS	Pyrrolopyrimidine compounds and their uses	Aug, 2029 (6 years from now)
US8962630	NOVARTIS	Pyrrolopyrimidine compounds and their uses	Dec, 2029 (7 years from now)

Drugs and Companies using RIBOCICLIB SUCCINATE ingredient

Treatment: In combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy; in combination with fulvestrant for the treatment of postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy; in combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer; in combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men, for the treatment of hr-positive, her2-negative advanced or metastatic breast cancer; in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; In combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer; in combination with fulvestrant for the treatment of postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy; in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy; in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; in combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men, for the treatment of hr-positive, her2-negative advanced or metastatic breast cancer

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 200MG BASE	TABLET;ORAL	Prescription

89. Drug name - KISQALI FEMARA CO-PACK (COPACKAGED)

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8415355	NOVARTIS	Pyrrolopyrimidine compounds and their uses	Aug, 2029 (6 years from now)
CN102186856B	NOVARTIS	Pyrrolopyrimidine Compounds As Cdk Inhibitors	Aug, 2029 (6 years from now)
CN102186856A	NOVARTIS	Pyrrolopyrimidine Compounds As Cdk Inhibitors	Aug, 2029 (6 years from now)
EP2331547B1	NOVARTIS	Pyrrolopyrimidine Compounds As Cdk Inhibitors	Aug, 2029 (6 years from now)
EP2331547A1	NOVARTIS	Pyrrolopyrimidine Compounds As Cdk Inhibitors	Aug, 2029 (6 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9416136	NOVARTIS	Pyrrolopyrimidine compounds and their uses	Aug, 2029 (6 years from now)
US8962630	NOVARTIS	Pyrrolopyrimidine compounds and their uses	Dec, 2029 (7 years from now)

Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient

Treatment: Treatment of pre/perimenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2.5MG;EQ 200MG BASE	TABLET;ORAL	Prescription

90. Drug name - KLISYRI

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7851470	ALMIRALL	Composition and methods for modulating a kinase cascade	Feb, 2029 (6 years from now)

Drugs and Companies using TIRBANIBULIN ingredient

Treatment: NA

Dosage: OINTMENT;TOPICAL

Strength	Dosage	Availability
1%	OINTMENT;TOPICAL	Prescription

91. Drug name - KYLEENA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561524	BAYER HLTHCARE	Inserter	Sep, 2029 (6 years from now)
US9615965	BAYER HLTHCARE	Inserter	Sep, 2029 (6 years from now)

Drugs and Companies using LEVONORGESTREL ingredient

Treatment: A method of positioning an intrauterine system (ius) by determining a depth of the uterus, holding an inserter handle with one hand, inserting the ius into the uterus, and retracting a slider on the handle to release the ius into the uterus; A method of positioning an intrauterine system by holding an inserter handle with one hand, advancing the inserter through the cervix and into the uterus, and retracting a slider on the handle to release the intrauterine system

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

Strength	Dosage	Availability
19.5MG	INTRAUTERINE DEVICE;INTRAUTERINE	Prescription

92. Drug name - KYNMOBI

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10821074	SUNOVION PHARMS INC	Sublingual and buccal film compositions	Aug, 2029 (6 years from now)

Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: FILM;SUBLINGUAL

Strength	Dosage	Availability
10MG	FILM;SUBLINGUAL	Prescription
15MG	FILM;SUBLINGUAL	Prescription
20MG	FILM;SUBLINGUAL	Prescription
25MG	FILM;SUBLINGUAL	Prescription
30MG	FILM;SUBLINGUAL	Prescription

93. Drug name - KYPROLIS

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9511109	ONYX THERAP	Combination therapy with peptide epoxyketones	Oct, 2029 (7 years from now)

Drugs and Companies using CARFILZOMIB ingredient

Treatment: Kyprolis is indicated in combination with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
10MG/VIAL	POWDER;INTRAVENOUS	Prescription
30MG/VIAL	POWDER;INTRAVENOUS	Prescription
60MG/VIAL	POWDER;INTRAVENOUS	Prescription

94. Drug name - LAMICTAL ODT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7919115	GLAXOSMITHKLINE LLC	Orally disintegrating tablet compositions of lamotrigine	Jan, 2029 (6 years from now)

Drugs and Companies using LAMOTRIGINE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

Strength	Dosage	Availability
25MG	TABLET, ORALLY DISINTEGRATING;ORAL	Prescription
50MG	TABLET, ORALLY DISINTEGRATING;ORAL	Prescription
100MG	TABLET, ORALLY DISINTEGRATING;ORAL	Prescription
200MG	TABLET, ORALLY DISINTEGRATING;ORAL	Prescription

95. Drug name - LEQVIO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8106022	NOVARTIS	Carbohydrate conjugates as delivery agents for oligonucleotides	Dec, 2029 (7 years from now)

Drugs and Companies using INCLISIRAN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML)	SOLUTION;SUBCUTANEOUS	Prescription

96. Drug name - LO LOESTRIN FE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7704984	APIL	Extended estrogen dosing contraceptive regimen	Feb, 2029 (6 years from now)

Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ACETATE ingredient

Treatment: Lo loestrin fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception

Dosage: TABLET;ORAL

Strength	Dosage	Availability
0.01MG,0.01MG;1MG,N/A	TABLET;ORAL	Prescription

97. Drug name - LO MINASTRIN FE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7704984	APIL	Extended estrogen dosing contraceptive regimen	Feb, 2029 (6 years from now)

Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ACETATE ingredient

Treatment: Prevention of pregnancy

Dosage: TABLET, CHEWABLE, TABLET;ORAL

Strength	Dosage	Availability
0.01MG,0.01MG,N/A;1MG,N/A,N/A	TABLET, CHEWABLE, TABLET;ORAL	Discontinued

98. Drug name - LONHALA MAGNAIR KIT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10940110	SUNOVION RESP	Method and system for the treatment of chronic COPD with nebulized anticholinergic administrations	Feb, 2029 (6 years from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Treatment: Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd)

Dosage: SOLUTION;INHALATION

Strength	Dosage	Availability
25MCG/ML	SOLUTION;INHALATION	Prescription

99. Drug name - LONSURF

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE46284	TAIHO ONCOLOGY	Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor	Sep, 2029 (6 years from now)

Drugs and Companies using TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE ingredient

Treatment: Treatment of adults with metastatic gastric or gja previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropiate, her2/neu-targeted therapy; treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and if ras wild-type, an anti-egfr therapy

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 6.14MG BASE;15MG	TABLET;ORAL	Prescription
EQ 8.19MG BASE;20MG	TABLET;ORAL	Prescription

100. Drug name - LYNPARZA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8475842	ASTRAZENECA	Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one	Dec, 2029 (7 years from now)

Drugs and Companies using OLAPARIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
100MG	TABLET;ORAL	Prescription
150MG	TABLET;ORAL	Prescription

101. Drug name - MILPROSA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10537584	FERRING PHARMS INC	Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof	Feb, 2029 (6 years from now)
US10548904	FERRING PHARMS INC	Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof	Feb, 2029 (6 years from now)

Drugs and Companies using PROGESTERONE ingredient

Treatment: Method of supporting embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology (art) treatment program for infertile women

Dosage: SYSTEM;VAGINAL

Strength	Dosage	Availability
1.78GM	SYSTEM;VAGINAL	Discontinued

102. Drug name - MIRAPEX ER

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8679533	BOEHRINGER INGELHEIM	Pramipexole once-daily dosage form	Sep, 2029 (6 years from now)

Drugs and Companies using PRAMIPEXOLE DIHYDROCHLORIDE ingredient

Treatment: Treatment of parkinson's disease

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
0.375MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
0.75MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
1.5MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
2.25MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
3MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
3.75MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
4.5MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

103. Drug name - MIRENA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9615965	BAYER HLTHCARE	Inserter	Sep, 2029 (6 years from now)
US10561524	BAYER HLTHCARE	Inserter	Sep, 2029 (6 years from now)

Drugs and Companies using LEVONORGESTREL ingredient

Treatment: A method of positioning an intrauterine system by holding an inserter handle with one hand, advancing the inserter through the cervix and into the uterus, and retracting a slider on the handle to release the intrauterine system; A method of positioning an intrauterine system (ius) by determining a depth of the uterus, holding an inserter handle with one hand, inserting the ius into the uterus, and retracting a slider on the handle to release the ius into the uterus

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

Strength	Dosage	Availability
52MG	INTRAUTERINE DEVICE;INTRAUTERINE	Prescription

104. Drug name - MITOSOL

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7806265	MOBIUS THERAP	Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application	Feb, 2029 (6 years from now)
US9649428	MOBIUS THERAP	Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application	May, 2029 (6 years from now)

Drugs and Companies using MITOMYCIN ingredient

Treatment: Mitosol is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery. it is intended for topical application to the site of glaucoma filtration surgery

Dosage: FOR SOLUTION;TOPICAL

Strength	Dosage	Availability
0.2MG/VIAL	FOR SOLUTION;TOPICAL	Prescription

105. Drug name - MONOFERRIC

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10414831	PHARMACOSMOS AS	Stable iron oligosaccharide compound	Mar, 2029 (6 years from now)
US8815301	PHARMACOSMOS AS	Stable iron oligosaccharide compound	Aug, 2029 (6 years from now)
IN291100B	PHARMACOSMOS AS	A Stable Iron Oligosaccharide Compound	Mar, 2029 (6 years from now)
IN201108145P1	PHARMACOSMOS AS	A Stable Iron Oligosaccharide Compound	Mar, 2029 (6 years from now)
EP2411053B1	PHARMACOSMOS AS	A Stable Iron Oligosaccharide Compound	Mar, 2029 (6 years from now)
EP3156075A1	PHARMACOSMOS AS	An Oligosaccharide And A Process For Preparation Thereof	Mar, 2029 (6 years from now)
EP3156075B1	PHARMACOSMOS AS	An Oligosaccharide And A Process For Preparation Thereof	Mar, 2029 (6 years from now)
EP2411053A1	PHARMACOSMOS AS	A Stable Iron Oligosaccharide Compound	Mar, 2029 (6 years from now)

Drugs and Companies using FERRIC DERISOMALTOSE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
1GM/10ML (100MG/ML)	SOLUTION;INTRAVENOUS	Prescription
100MG/ML (100MG/ML)	SOLUTION;INTRAVENOUS	Discontinued
500MG/5ML (100MG/ML)	SOLUTION;INTRAVENOUS	Discontinued

106. Drug name - MOXEZA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8450311	NOVARTIS	Pharmaceutical compositions containing a fluoroquinolone antibiotic drug	May, 2029 (6 years from now)
US9114168	NOVARTIS	Pharmaceutical compositions containing a fluoroquinolone antibiotic drug	May, 2029 (6 years from now)

Drugs and Companies using MOXIFLOXACIN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
EQ 0.5% BASE	SOLUTION/DROPS;OPHTHALMIC	Prescription

107. Drug name - MULTAQ

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410167	SANOFI AVENTIS US	Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality	Apr, 2029 (6 years from now)
US9107900	SANOFI AVENTIS US	Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality	Apr, 2029 (6 years from now)

Drugs and Companies using DRONEDARONE HYDROCHLORIDE ingredient

Treatment: Reduction in risk of hospitalization in patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a day with morning and evening meals; treatment of patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a day with morning and evening meals; Reduction in risk of hospitalization in patients with stable nyha class iii heart failure and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning and evening meals; reduction in risk of hospitalization in patients with coronary heart disease and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning and evening meals

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 400MG BASE	TABLET;ORAL	Prescription

108. Drug name - MYCAPSSA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8329198	AMRYT	Pharmaceutical compositions and related methods of delivery	Sep, 2029 (6 years from now)
US8535695	AMRYT	Pharmaceutical compositions and related methods of delivery	Sep, 2029 (6 years from now)
US9265812	AMRYT	Pharmaceutical compositions and related methods of delivery	Sep, 2029 (6 years from now)
US9566246	AMRYT	Pharmaceutical compositions and related methods of delivery	Sep, 2029 (6 years from now)

Drugs and Companies using OCTREOTIDE ACETATE ingredient

Treatment: Use of oral octreotide for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide

Dosage: CAPSULE, DELAYED RELEASE;ORAL

Strength	Dosage	Availability
EQ 20MG BASE	CAPSULE, DELAYED RELEASE;ORAL	Prescription

109. Drug name - MYDAYIS

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846100	TAKEDA PHARMS USA	Controlled dose drug delivery system	Aug, 2029 (6 years from now)

Drugs and Companies using AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE ingredient

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
3.125MG;3.125MG;3.125MG;3.125MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
6.25MG;6.25MG;6.25MG;6.25MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
9.375MG;9.375MG;9.375MG;9.375MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
12.5MG;12.5MG;12.5MG;12.5MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

110. Drug name - MYRBETRIQ

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8772315 (Pediatric)	APGDI	Pharmaceutical composition for treating overactive bladder	Apr, 2029 (6 years from now)
US10842780	APGDI	Pharmaceutical composition for modified release	Sep, 2029 (6 years from now)

Drugs and Companies using MIRABEGRON ingredient

Treatment: Administration of an extended release tablet for the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
25MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
50MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

111. Drug name - NAMENDA XR

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8039009	ALLERGAN	Modified release formulations of memantine oral dosage forms	Mar, 2029 (6 years from now)
US8039009 (Pediatric)	ALLERGAN	Modified release formulations of memantine oral dosage forms	Sep, 2029 (6 years from now)

Drugs and Companies using MEMANTINE HYDROCHLORIDE ingredient

Treatment: Treatment of moderate to severe dementia of the alzheimer's type

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
7MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
14MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
21MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
28MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

112. Drug name - NAMZARIC

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8039009	ALLERGAN	Modified release formulations of memantine oral dosage forms	Mar, 2029 (6 years from now)
US8039009 (Pediatric)	ALLERGAN	Modified release formulations of memantine oral dosage forms	Sep, 2029 (6 years from now)
US8058291	ALLERGAN	Methods and compositions for the treatment of CNS-related conditions	Dec, 2029 (7 years from now)

Drugs and Companies using DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE ingredient

Treatment: Memantine hcl/donepezil hcl combination for the treatment of moderate to severe dementia of the alzheimer's type

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
10MG;7MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
10MG;14MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
10MG;21MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
10MG;28MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

113. Drug name - NERLYNX

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265784	PUMA BIOTECH	Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine	Aug, 2029 (6 years from now)

Drugs and Companies using NERATINIB MALEATE ingredient

Treatment: Use in combination with capecitabine, for the treatment of adult patients with advanced or metastatic her2-positive breast cancer who have received two or more prior anti-her2 based regimens in the metastatic setting

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 40MG BASE	TABLET;ORAL	Prescription

114. Drug name - NESINA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8697125	TAKEDA PHARMS USA	Tablet preparation without causing a tableting trouble	Jun, 2029 (6 years from now)

Drugs and Companies using ALOGLIPTIN BENZOATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 6.25MG BASE	TABLET;ORAL	Prescription
EQ 12.5MG BASE	TABLET;ORAL	Prescription
EQ 25MG BASE	TABLET;ORAL	Prescription

115. Drug name - NEURACEQ

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7807135	LIFE MOLECULAR	Stilbene derivatives and their use for binding and imaging amyloid plaques	Mar, 2029 (6 years from now)
EP2213652B1	LIFE MOLECULAR	Stilbene Derivatives And Their Use For Binding And Imaging Amyloid Plaques	Feb, 2029 (6 years from now)
EP2213652A1	LIFE MOLECULAR	Stilbene Derivatives And Their Use For Binding And Imaging Amyloid Plaques	Feb, 2029 (6 years from now)

Drugs and Companies using FLORBETABEN F-18 ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
30ML (1.4-135mCi/ML)	SOLUTION;INTRAVENOUS	Prescription

116. Drug name - NEXTERONE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7635773	BAXTER HLTHCARE	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (6 years from now)

Drugs and Companies using AMIODARONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: INJECTABLE;INJECTION

Strength	Dosage	Availability
50MG/ML	INJECTABLE;INJECTION	Discontinued
150MG/100ML (1.5MG/ML)	INJECTABLE;INJECTION	Prescription
360MG/200ML (1.8MG/ML)	INJECTABLE;INJECTION	Prescription

117. Drug name - NICORETTE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8940772	GLAXOSMITHKLINE	Nicotine lozenge composition	Apr, 2029 (6 years from now)
US8501164	GLAXOSMITHKLINE	Nicotine lozenge compositions	Jun, 2029 (6 years from now)

Drugs and Companies using NICOTINE POLACRILEX ingredient

Treatment: NA

Dosage: TROCHE/LOZENGE;ORAL

Strength	Dosage	Availability
EQ 2MG BASE	TROCHE/LOZENGE;ORAL	Over the counter
EQ 4MG BASE	TROCHE/LOZENGE;ORAL	Over the counter

118. Drug name - NINLARO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8859504	TAKEDA PHARMS USA	Boronate ester compounds and pharmaceutical compositions thereof	Jun, 2029 (6 years from now)
US7442830	TAKEDA PHARMS USA	Proteasome inhibitors	Nov, 2029 (7 years from now)
IN290327B	TAKEDA PHARMS USA	Boronate Ester Compounds And Pharmaceutical Compositions Thereof	Jun, 2029 (6 years from now)
IN201100107P1	TAKEDA PHARMS USA	Boronate Ester Compounds And Pharmaceutical Compositions Thereof	Jun, 2029 (6 years from now)
EP2318419B1	TAKEDA PHARMS USA	Boronate Ester Compounds And Pharmaceutical Compositions Thereof	Jun, 2029 (6 years from now)
EP2318419A1	TAKEDA PHARMS USA	Boronate Ester Compounds And Pharmaceutical Compositions Thereof	Jun, 2029 (6 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9175017	TAKEDA PHARMS USA	Boronate ester compounds and pharmaceutical compositions thereof	Jun, 2029 (6 years from now)

Drugs and Companies using IXAZOMIB CITRATE ingredient

Treatment: Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 2.3MG BASE	CAPSULE;ORAL	Prescription
EQ 3MG BASE	CAPSULE;ORAL	Prescription
EQ 4MG BASE	CAPSULE;ORAL	Prescription

119. Drug name - NITROLINGUAL

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7872049	POHL BOSKAMP	Long-term stable pharmaceutical preparation containing the active ingredient glyceryl trinitrate	Mar, 2029 (6 years from now)

Drugs and Companies using NITROGLYCERIN ingredient

Treatment: Method of treating angina pectoris

Dosage: SPRAY, METERED;SUBLINGUAL

Strength	Dosage	Availability
0.4MG/SPRAY	SPRAY, METERED;SUBLINGUAL	Prescription

120. Drug name - NOCDURNA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020448	FERRING PHARMS INC	Methods comprising desmopressin	May, 2029 (6 years from now)
US10137167	FERRING PHARMS INC	Methods comprising desmopressin	May, 2029 (6 years from now)

Drugs and Companies using DESMOPRESSIN ACETATE ingredient

Treatment: Treatment of nocturia due to nocturnal polyuria in adults, comprising monitoring a patient's serum sodium concentration

Dosage: TABLET;SUBLINGUAL

Strength	Dosage	Availability
0.0277MG	TABLET;SUBLINGUAL	Prescription
0.0553MG	TABLET;SUBLINGUAL	Prescription

121. Drug name - NOXAFIL

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10117951	MERCK SHARP DOHME	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (6 years from now)
US8410077	MERCK SHARP DOHME	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (6 years from now)
US9750822	MERCK SHARP DOHME	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (6 years from now)

Drugs and Companies using POSACONAZOLE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
300MG/16.7ML (18MG/ML)	SOLUTION;INTRAVENOUS	Prescription

122. Drug name - NUZYRA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265740	PARATEK PHARMS INC	Minocycline compounds and methods of use thereof	Mar, 2029 (6 years from now)
US10124014	PARATEK PHARMS INC	Minocycline compounds and methods of use thereof	Mar, 2029 (6 years from now)
US9724358	PARATEK PHARMS INC	Minocycline compounds and methods of use thereof	Mar, 2029 (6 years from now)

Drugs and Companies using OMADACYCLINE TOSYLATE ingredient

Treatment: Treatment of bacterial skin and skin structure infection; Treatment of bacterial skin and skin structure infections

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 150MG BASE	TABLET;ORAL	Prescription

123. Drug name - ODOMZO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8178563	SUN PHARM	Compounds and compositions as hedgehog pathway modulators	Jul, 2029 (6 years from now)
US8063043	SUN PHARM	Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide	Sep, 2029 (6 years from now)
CN102159570B	SUN PHARM	Salts Of N-[6-Cis-2,6-Dimethylmorpholin-4Yl)Pyridine-3Yl]-2-Methyl-4'-(Trifluoromethoxy)[1,1'-Biphenyl]-3-Carboxamide	Sep, 2029 (6 years from now)
CN102159570A	SUN PHARM	Salts Of N-[6-Cis-2,6-Dimethylmorpholin-4Yl)Pyridine-3Yl]-2-Methyl-4'-(Trifluoromethoxy)[1,1'-Biphenyl]-3-Carboxamide	Sep, 2029 (6 years from now)
EP2342198B1	SUN PHARM	A Diphosphate Salt Of N-[6-Cis-2,6-Dimethylmorpholin-4Yl)Pyridine-3Yl]-2-Methyl-4'-(Trifluoromethoxy)[1,1'-Biphenyl]-3-Carboxamide	Sep, 2029 (6 years from now)
EP2342198A1	SUN PHARM	A Diphosphate Salt Of N-[6-Cis-2,6-Dimethylmorpholin-4Yl)Pyridine-3Yl]-2-Methyl-4'-(Trifluoromethoxy)[1,1'-Biphenyl]-3-Carboxamide	Sep, 2029 (6 years from now)

Drugs and Companies using SONIDEGIB PHOSPHATE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 200MG BASE	CAPSULE;ORAL	Prescription

124. Drug name - OFEV

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10105323	BOEHRINGER INGELHEIM	Pharmaceutical dosage form for immediate release of an indolinone derivative	Jun, 2029 (6 years from now)
US9907756	BOEHRINGER INGELHEIM	Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative	Jun, 2029 (6 years from now)

Drugs and Companies using NINTEDANIB ESYLATE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 100MG BASE	CAPSULE;ORAL	Prescription
EQ 150MG BASE	CAPSULE;ORAL	Prescription

125. Drug name - OFIRMEV

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9987238 (Pediatric)	MALLINCKRODT HOSP	Reduced dose intravenous acetaminophen	May, 2029 (6 years from now)
US9610265 (Pediatric)	MALLINCKRODT HOSP	Reduced dose intravenous acetaminophen	May, 2029 (6 years from now)

Drugs and Companies using ACETAMINOPHEN ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
1GM/100ML (10MG/ML)	SOLUTION;INTRAVENOUS	Discontinued

126. Drug name - OLEPTRO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8133893	ANGELINI PHARMA	Trazodone and trazodone hydrochloride in purified form	Mar, 2029 (6 years from now)

Drugs and Companies using TRAZODONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
150MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
300MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued

127. Drug name - OLUMIANT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420629	ELI LILLY AND CO	Azetidine and cyclobutane derivatives as JAK inhibitors	Mar, 2029 (6 years from now)

Drugs and Companies using BARICITINIB ingredient

Treatment: Treatment of rheumatoid arthritis

Dosage: TABLET;ORAL

Strength	Dosage	Availability
1MG	TABLET;ORAL	Prescription
2MG	TABLET;ORAL	Prescription

128. Drug name - OLYSIO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8148399	JANSSEN PRODS	Macrocyclic inhibitors of hepatitis C virus	Sep, 2029 (6 years from now)

Drugs and Companies using SIMEPREVIR SODIUM ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 150MG BASE	CAPSULE;ORAL	Discontinued

129. Drug name - ONGENTYS

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8168793	NEUROCRINE	Nitrocatechol derivatives as COMT inhibitors	Apr, 2029 (6 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8524746	NEUROCRINE	Dosage regimen for COMT inhibitors	Jul, 2029 (6 years from now)

Drugs and Companies using OPICAPONE ingredient

Treatment: Method of treating parkinson's disease

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
25MG	CAPSULE;ORAL	Prescription
50MG	CAPSULE;ORAL	Prescription

130. Drug name - ONPATTRO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8168775	ALNYLAM PHARMS INC	Compositions and methods for inhibiting expression of transthyretin	Oct, 2029 (7 years from now)
US10240152	ALNYLAM PHARMS INC	Compositions and methods for inhibiting expression of transthyretin	Oct, 2029 (7 years from now)
CN102186978B	ALNYLAM PHARMS INC	Compositions And Methods For Inhibiting Expression Of Transthyretin	Oct, 2029 (7 years from now)
CN103937793B	ALNYLAM PHARMS INC	Compositions And Methods For Inhibiting Expression Of Transthyretin	Oct, 2029 (7 years from now)
CN106834291A	ALNYLAM PHARMS INC	Compositions And Methods For Inhibiting Expression Of Transthyretin	Oct, 2029 (7 years from now)
CN106834291B	ALNYLAM PHARMS INC	Compositions And Methods For Inhibiting Expression Of Transthyretin	Oct, 2029 (7 years from now)
CN102186978A	ALNYLAM PHARMS INC	Compositions And Methods For Inhibiting Expression Of Transthyretin	Oct, 2029 (7 years from now)
CN103937793A	ALNYLAM PHARMS INC	Compositions And Methods For Inhibiting Expression Of Transthyretin	Oct, 2029 (7 years from now)
IN307782B	ALNYLAM PHARMS INC	Compositions And Methods For Inhibiting Expression Of Transthyretin	Oct, 2029 (7 years from now)
IN201103301P4	ALNYLAM PHARMS INC	Compositions And Methods For Inhibiting Expression Of Transthyretin	Oct, 2029 (7 years from now)
EP2344639A2	ALNYLAM PHARMS INC	Compositions And Methods For Inhibiting Expression Of Transthyretin	Oct, 2029 (7 years from now)
EP3354733A1	ALNYLAM PHARMS INC	Compositions And Methods For Inhibiting Expression Of Transthyretin	Oct, 2029 (7 years from now)
EP2344639B1	ALNYLAM PHARMS INC	Compositions And Methods For Inhibiting Expression Of Transthyretin	Oct, 2029 (7 years from now)
EP3354733B1	ALNYLAM PHARMS INC	Compositions And Methods For Inhibiting Expression Of Transthyretin	Oct, 2029 (7 years from now)
EP2937418A1	ALNYLAM PHARMS INC	Compositions And Methods For Inhibiting Expression Of Transthyretin	Oct, 2029 (7 years from now)
EP2937418B1	ALNYLAM PHARMS INC	Compositions And Methods For Inhibiting Expression Of Transthyretin	Oct, 2029 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8492359	ALNYLAM PHARMS INC	Lipid formulations for nucleic acid delivery	Apr, 2029 (6 years from now)
US8822668	ALNYLAM PHARMS INC	Lipid formulations for nucleic acid delivery	Apr, 2029 (6 years from now)
US9364435	ALNYLAM PHARMS INC	Lipid formulations for nucleic acid delivery	Apr, 2029 (6 years from now)
US11141378	ALNYLAM PHARMS INC	Lipid formulations for nucleic acid delivery	Apr, 2029 (6 years from now)
US8058069	ALNYLAM PHARMS INC	Lipid formulations for nucleic acid delivery	Apr, 2029 (6 years from now)
US8741866	ALNYLAM PHARMS INC	Compositions and methods for inhibiting expression of transthyretin	Oct, 2029 (7 years from now)
US9234196	ALNYLAM PHARMS INC	Compositions and methods for inhibiting expression of transthyretin	Oct, 2029 (7 years from now)

Drugs and Companies using PATISIRAN SODIUM ingredient

Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription

131. Drug name - ONZETRA XSAIL

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10076615	CURRAX	Nasal delivery	Jul, 2029 (6 years from now)
US8550073	CURRAX	Nasal delivery	Oct, 2029 (7 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Treatment: Treatment of migraine via delivery of sumatriptan via the nasal cavity; acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device; method of delivering sumatriptan to a nasal cavity

Dosage: POWDER;NASAL

Strength	Dosage	Availability
EQ 11MG BASE	POWDER;NASAL	Prescription

132. Drug name - OPANA ER

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7851482	ENDO PHARMS	Method for making analgesics	Jul, 2029 (6 years from now)
US8871779	ENDO PHARMS	Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds	Nov, 2029 (7 years from now)

Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
5MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
7.5MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
10MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
15MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
20MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
30MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
40MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued

133. Drug name - OPSUMIT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8268847	ACTELION	Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor	Apr, 2029 (6 years from now)

Drugs and Companies using MACITENTAN ingredient

Treatment: Method of treating pulmonary hypertension comprising administering macitentan in combination with a compound having phosphodiesterase-5 inhibitory properties

Dosage: TABLET;ORAL

Strength	Dosage	Availability
10MG	TABLET;ORAL	Prescription

134. Drug name - ORBACTIV

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420592	MELINTA THERAP	Methods of treatment using single doses of oritavancin	Aug, 2029 (6 years from now)

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

Treatment: Treatment of bacterial skin and skin structure infections using a single dose

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
EQ 400MG BASE/VIAL	POWDER;INTRAVENOUS	Prescription

135. Drug name - ORKAMBI

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10646481	VERTEX PHARMS INC	Pharmaceutical composition and administrations thereof	Aug, 2029 (6 years from now)
US9192606	VERTEX PHARMS INC	Dosage units of 3-(6-(1-(2,2-difluorobenzo[d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid	Sep, 2029 (6 years from now)

Drugs and Companies using IVACAFTOR; LUMACAFTOR ingredient

Treatment: Method of treating cystic fibrosis in a patient, the patient having the f508del mutation in cftr, using a dosage unit as defined in claim 1 of u.s. patent no. 9,192,606

Dosage: GRANULE;ORAL

Strength	Dosage	Availability
125MG/PACKET;100MG/PACKET	GRANULE;ORAL	Prescription
188MG/PACKET;150MG/PACKET	GRANULE;ORAL	Prescription

136. Drug name - OSENI

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8637079	TAKEDA PHARMS USA	Solid preparation comprising alogliptin and pioglitazone	Jun, 2029 (6 years from now)

Drugs and Companies using ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 12.5MG BASE;EQ 15MG BASE	TABLET;ORAL	Prescription
EQ 12.5MG BASE;EQ 30MG BASE	TABLET;ORAL	Prescription
EQ 12.5MG BASE;EQ 45MG BASE	TABLET;ORAL	Prescription
EQ 25MG BASE;EQ 15MG BASE	TABLET;ORAL	Prescription
EQ 25MG BASE;EQ 30MG BASE	TABLET;ORAL	Prescription
EQ 25MG BASE;EQ 45MG BASE	TABLET;ORAL	Prescription

137. Drug name - OTIPRIO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9603796	ALK ABELLO	Controlled release antimicrobial compositions and methods for the treatment of otic disorders	Apr, 2029 (6 years from now)
CN102026623A	ALK ABELLO	Controlled Release Corticosteroid Compositions And Methods For The Treatment Of Otic Disorders	May, 2029 (6 years from now)
CN102026623B	ALK ABELLO	Controlled Release Corticosteroid Compositions And Methods For The Treatment Of Otic Disorders	May, 2029 (6 years from now)
CN104352429B	ALK ABELLO	For Controlled Release Antimicrobial Compositions And Methods For The Treatment Of Otic Disorders	Jul, 2029 (6 years from now)
CN104352429A	ALK ABELLO	Controlled Release Antimicrobial Composition And Method For Treating Ear Part Condition	Jul, 2029 (6 years from now)
EP2303227A4	ALK ABELLO	Controlled Release Corticosteroid Compositions And Methods For The Treatment Of Otic Disorders	May, 2029 (6 years from now)
EP2303227A2	ALK ABELLO	Controlled Release Corticosteroid Compositions And Methods For The Treatment Of Otic Disorders	May, 2029 (6 years from now)
EP2303227B1	ALK ABELLO	Controlled Release Corticosteroid Compositions And Methods For The Treatment Of Otic Disorders	May, 2029 (6 years from now)
EP2299979A4	ALK ABELLO	Controlled Release Antimicrobial Compositions And Methods For The Treatment Of Otic Disorders	Jul, 2029 (6 years from now)
EP2299979B1	ALK ABELLO	Controlled Release Antimicrobial Compositions And Methods For The Treatment Of Otic Disorders	Jul, 2029 (6 years from now)
EP2299979A2	ALK ABELLO	Controlled Release Antimicrobial Compositions And Methods For The Treatment Of Otic Disorders	Jul, 2029 (6 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9205048	ALK ABELLO	Controlled release antimicrobial compositions and methods for the treatment of otic disorders	Apr, 2029 (6 years from now)
US9233068	ALK ABELLO	Controlled release antimicrobial compositions and methods for the treatment of OTIC disorders	Dec, 2029 (7 years from now)

Drugs and Companies using CIPROFLOXACIN ingredient

Treatment: Treatment of pediatric patients with otitis media with effusion undergoing tympanostomy tube placement

Dosage: INJECTABLE, SUSPENSION;OTIC

Strength	Dosage	Availability
6% (60MG/ML)	INJECTABLE, SUSPENSION;OTIC	Prescription

138. Drug name - OTREXUP

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10709844	OTTER PHARMS	Injector safety device	Mar, 2029 (6 years from now)
US9867949	OTTER PHARMS	Injector safety device	Mar, 2029 (6 years from now)

Drugs and Companies using METHOTREXATE ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
7.5MG/0.4ML (7.5MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Discontinued
10MG/0.4ML (10MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Discontinued
12.5MG/0.4ML (12.5MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Prescription
15MG/0.4ML (15MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Prescription
17.5MG/0.4ML (17.5MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Prescription
20MG/0.4ML (20MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Prescription
22.5MG/0.4ML (22.5MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Prescription
25MG/0.4ML (25MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Prescription
15MG/0.6ML (15MG/0.6ML)	SOLUTION;SUBCUTANEOUS	Discontinued
17.5MG/0.7ML (17.5MG/0.7ML)	SOLUTION;SUBCUTANEOUS	Discontinued
20MG/0.8ML (20MG/0.8ML)	SOLUTION;SUBCUTANEOUS	Discontinued
22.5MG/0.9ML (22.5MG/0.9ML)	SOLUTION;SUBCUTANEOUS	Discontinued
25MG/ML (25MG/ML)	SOLUTION;SUBCUTANEOUS	Discontinued

139. Drug name - OXLUMO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8106022	ALNYLAM PHARMS INC	Carbohydrate conjugates as delivery agents for oligonucleotides	Dec, 2029 (7 years from now)

Drugs and Companies using LUMASIRAN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
EQ 94.5MG/0.5ML BASE (EQ 94.5MG/0.5ML BASE)	SOLUTION;SUBCUTANEOUS	Prescription

140. Drug name - PENNSAID

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8741956	HORIZON	Treatment of pain with topical diclofenac	Jul, 2029 (6 years from now)
US8618164	HORIZON	Treatment of pain with topical diclofenac compounds	Jul, 2029 (6 years from now)
US9370501	HORIZON	Treatment of pain with topical diclofenac	Jul, 2029 (6 years from now)
US8217078	HORIZON	Treatment of pain with topical diclofenac	Jul, 2029 (6 years from now)
US9375412	HORIZON	Treatment of pain with topical diclofenac	Jul, 2029 (6 years from now)
US9415029	HORIZON	Treatment of pain with topical diclofenac	Jul, 2029 (6 years from now)

Drugs and Companies using DICLOFENAC SODIUM ingredient

Treatment: Combination use of topical diclofenac on the knee and administration of an oral nsaid.; Use of topical diclofenac on the knee and a second topical prescription medication on the same knee; Use of topical diclofenac sodium for treating pain

Dosage: SOLUTION;TOPICAL

Strength	Dosage	Availability
2%	SOLUTION;TOPICAL	Prescription

141. Drug name - PENNSAID

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8217078	NUVO PHARMS INC	Treatment of pain with topical diclofenac	Jul, 2029 (6 years from now)
US8618164	NUVO PHARMS INC	Treatment of pain with topical diclofenac compounds	Jul, 2029 (6 years from now)
US8741956	NUVO PHARMS INC	Treatment of pain with topical diclofenac	Jul, 2029 (6 years from now)

Drugs and Companies using DICLOFENAC SODIUM ingredient

Treatment: Use of topical diclofenac on the knee and a second topical medication on the same knee; Use of topical diclofenac on the knee and a second topical prescription medication on the same knee; Combination use of topical diclofenac on the knee and administration of an oral nsaid.

Dosage: SOLUTION;TOPICAL

Strength	Dosage	Availability
1.5%	SOLUTION;TOPICAL	Discontinued

142. Drug name - PIQRAY

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8476268	NOVARTIS	Pyrrolidine-1,2-dicarboxamide derivatives	Sep, 2029 (6 years from now)
CN102149711B	NOVARTIS	Organic Compounds	Sep, 2029 (6 years from now)
CN102149711A	NOVARTIS	Organic Compounds	Sep, 2029 (6 years from now)
IN307469B	NOVARTIS	The Compound (S)-Pyrrolidine-1,2-Dicarboxylic Acid 2-Amide-1- ({4-Methyl-5-[2-(2,2,2-Trifluoro-1,1-Dimethyl-Ethyl)- Pyridin-4-Yl]-Thiazol-2-Yl}-Amide)	Sep, 2029 (6 years from now)
EP2331537A1	NOVARTIS	1-((5-Heteroarylthiazol-2-Yl)Aminocarbonyl)Pyrrolidine-2-Carboxamide Derivatives As Phosphatidylinositol 3-Kinase (Pi3K) Inhibitors Useful In The Treatment Of Proliferative Diseases	Sep, 2029 (6 years from now)
EP2331537B1	NOVARTIS	1-((5-Heteroarylthiazol-2-Yl)Aminocarbonyl)Pyrrolidine-2-Carboxamide Derivatives As Phosphatidylinositol 3-Kinase (Pi3K) Inhibitors Useful In The Treatment Of Proliferative Diseases	Sep, 2029 (6 years from now)

Drugs and Companies using ALPELISIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
50MG	TABLET;ORAL	Prescription
150MG	TABLET;ORAL	Prescription
200MG	TABLET;ORAL	Prescription

143. Drug name - PRESTALIA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7846961	ADHERA	α crystalline form of the arginine salt of perindopril, a process for its preparation and pharmaceutical compositions containing it	Oct, 2029 (7 years from now)

Drugs and Companies using AMLODIPINE BESYLATE; PERINDOPRIL ARGININE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 2.5MG BASE;3.5MG	TABLET;ORAL	Prescription
EQ 5MG BASE;7MG	TABLET;ORAL	Prescription
EQ 10MG BASE;14MG	TABLET;ORAL	Prescription

144. Drug name - PREZCOBIX

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8148374	JANSSEN PRODS	Modulators of pharmacokinetic properties of therapeutics	Sep, 2029 (6 years from now)

Drugs and Companies using COBICISTAT; DARUNAVIR ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
150MG;800MG	TABLET;ORAL	Prescription

145. Drug name - PYLARIFY

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9861713	PROGENICS PHARMS INC	PSMA-binding agents and uses thereof	Jul, 2029 (6 years from now)
CN107382846B	PROGENICS PHARMS INC	Psma-Binding Agents And Uses Thereof	Jul, 2029 (6 years from now)
CN102171187A	PROGENICS PHARMS INC	Psma-Binding Agents And Uses Thereof	Jul, 2029 (6 years from now)
CN102171187B	PROGENICS PHARMS INC	Psma- Binding Agent And Use Thereof	Jul, 2029 (6 years from now)
CN107382846A	PROGENICS PHARMS INC	Psma- Binding Agent And Use Thereof	Jul, 2029 (6 years from now)
IN315927B	PROGENICS PHARMS INC	Psma-Binding Agents And Uses Thereof	Jul, 2029 (6 years from now)
EP2318366B1	PROGENICS PHARMS INC	Psma-Binding Agents And Uses Thereof	Jul, 2029 (6 years from now)
EP3222615B1	PROGENICS PHARMS INC	Psma-Binding Agents And Uses Thereof	Jul, 2029 (6 years from now)
EP2318366A2	PROGENICS PHARMS INC	Psma-Binding Agents And Uses Thereof	Jul, 2029 (6 years from now)
EP2318366A4	PROGENICS PHARMS INC	Psma-Binding Agents And Uses Thereof	Jul, 2029 (6 years from now)
EP3222615A1	PROGENICS PHARMS INC	Psma-Binding Agents And Uses Thereof	Jul, 2029 (6 years from now)

Drugs and Companies using PIFLUFOLASTAT F-18 ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
50ML (1-80mCi/ML)	SOLUTION;INTRAVENOUS	Prescription

146. Drug name - QBREXZA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8618160	JOURNEY	Topical glycopyrrolate formulations	Dec, 2029 (7 years from now)

Drugs and Companies using GLYCOPYRRONIUM TOSYLATE ingredient

Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older

Dosage: CLOTH;TOPICAL

Strength	Dosage	Availability
EQ 2.4% BASE	CLOTH;TOPICAL	Prescription

147. Drug name - QSYMIA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8580298	VIVUS	Low dose topiramate/phentermine composition and methods of use thereof	May, 2029 (6 years from now)
US8580299	VIVUS	Escalating dosing regimen for effecting weight loss and treating obesity	Jun, 2029 (6 years from now)

Drugs and Companies using PHENTERMINE HYDROCHLORIDE; TOPIRAMATE ingredient

Treatment: Use of qsymia (phentermine and topiramate) for weight management, including, but not limited to effecting weight loss, treating obesity, and/or treating overweight

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
EQ 3.75MG BASE;23MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
EQ 7.5MG BASE;46MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
EQ 11.25MG BASE;69MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
EQ 15MG BASE;92MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

148. Drug name - QTERN

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7919598	ASTRAZENECA AB	Crystal structures of SGLT2 inhibitors and processes for preparing same	Dec, 2029 (7 years from now)

Drugs and Companies using DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
5MG;EQ 5MG BASE	TABLET;ORAL	Prescription
10MG;EQ 5MG BASE	TABLET;ORAL	Prescription

149. Drug name - QTERNMET XR

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7919598	ASTRAZENECA AB	Crystal structures of SGLT2 inhibitors and processes for preparing same	Dec, 2029 (7 years from now)

Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
2.5MG;1GM;EQ 2.5MG BASE	TABLET, EXTENDED RELEASE;ORAL	Discontinued
5MG;1GM;EQ 2.5MG BASE	TABLET, EXTENDED RELEASE;ORAL	Discontinued
5MG;1GM;EQ 5MG BASE	TABLET, EXTENDED RELEASE;ORAL	Discontinued
10MG;1GM;EQ 5MG BASE	TABLET, EXTENDED RELEASE;ORAL	Discontinued

150. Drug name - QUARTETTE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8415332	TEVA BRANDED PHARM	Methods of hormonal treatment utilizing ascending-dose extended cycle regimens	Mar, 2029 (6 years from now)

Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	TABLET;ORAL	Prescription

151. Drug name - QUILLIVANT XR

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8062667	NEXTWAVE	Modified release formulations containing drug-ion exchange resin complexes	Mar, 2029 (6 years from now)

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
5MG/ML	FOR SUSPENSION, EXTENDED RELEASE;ORAL	Prescription

152. Drug name - RASUVO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8664231	MEDEXUS	Concentrated methotrexate solutions	Jun, 2029 (6 years from now)

Drugs and Companies using METHOTREXATE ingredient

Treatment: Subcutaneous injection of methotrexate

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
7.5MG/0.15ML (7.5MG/0.15ML)	SOLUTION;SUBCUTANEOUS	Prescription
10MG/0.20ML (10MG/0.20ML)	SOLUTION;SUBCUTANEOUS	Prescription
12.5MG/0.25ML (12.5MG/0.25ML)	SOLUTION;SUBCUTANEOUS	Prescription
15MG/0.30ML (15MG/0.30ML)	SOLUTION;SUBCUTANEOUS	Prescription
17.5MG/0.35ML (17.5MG/0.35ML)	SOLUTION;SUBCUTANEOUS	Prescription
20MG/0.4ML (20MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Prescription
22.5MG/0.45ML (22.5MG/0.45ML)	SOLUTION;SUBCUTANEOUS	Prescription
25MG/0.5ML (25MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
27.5MG/0.55ML (27.5MG/0.55ML)	SOLUTION;SUBCUTANEOUS	Discontinued
30MG/0.6ML (30MG/0.6ML)	SOLUTION;SUBCUTANEOUS	Prescription

153. Drug name - RECARBRIO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8487093	MSD MERCK CO	β-lactamase inhibitors	Nov, 2029 (7 years from now)
CN102827067B	MSD MERCK CO	Beta-Lactamase Inhibitors	Jan, 2029 (6 years from now)
CN101918407B	MSD MERCK CO	Beta-Lactam Enzyme Inhibitor	Jan, 2029 (6 years from now)
CN102827067A	MSD MERCK CO	Beta-Lactamase Inhibitors	Jan, 2029 (6 years from now)
CN101918407A	MSD MERCK CO	Beta-1Actamase Inhibitors	Jan, 2029 (6 years from now)
IN293446B	MSD MERCK CO	Beta-Lactamase Inhibitors	Jan, 2029 (6 years from now)
IN201003977P4	MSD MERCK CO	Beta-Lactamase Inhibitors	Jan, 2029 (6 years from now)
EP2666774A1	MSD MERCK CO	Beta-Lactamase Inhibitors	Jan, 2029 (6 years from now)
EP2666774B1	MSD MERCK CO	Beta-Lactamase Inhibitors	Jan, 2029 (6 years from now)
EP2231667B1	MSD MERCK CO	Beta-Lactamase Inhibitors	Jan, 2029 (6 years from now)
EP2231667A2	MSD MERCK CO	Beta-Lactamase Inhibitors	Jan, 2029 (6 years from now)

Drugs and Companies using CILASTATIN SODIUM; IMIPENEM; RELEBACTAM ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL	POWDER;INTRAVENOUS	Prescription

154. Drug name - RELISTOR

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9180125	SALIX	Peripheral opioid receptor antagonists and uses thereof	Sep, 2029 (6 years from now)
US9492445	SALIX	Peripheral opioid receptor antagonists and uses thereof	Sep, 2029 (6 years from now)
US8420663	SALIX	Peripheral opioid receptor antagonists and uses thereof	Sep, 2029 (6 years from now)
US9724343	SALIX	Peripheral opioid receptor antagonists and uses thereof	Sep, 2029 (6 years from now)

Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient

Treatment: Treatment of opioid-induced constipation

Dosage: TABLET;ORAL

Strength	Dosage	Availability
150MG	TABLET;ORAL	Prescription

155. Drug name - RELISTOR

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9492445	SALIX PHARMS	Peripheral opioid receptor antagonists and uses thereof	Sep, 2029 (6 years from now)
US8822490	SALIX PHARMS	Peripheral opioid receptor antagonists and uses thereof	Sep, 2029 (6 years from now)
US9180125	SALIX PHARMS	Peripheral opioid receptor antagonists and uses thereof	Sep, 2029 (6 years from now)
US8420663	SALIX PHARMS	Peripheral opioid receptor antagonists and uses thereof	Sep, 2029 (6 years from now)

Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient

Treatment: Treatment of opioid-induced constipation

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
8MG/0.4ML (8MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Prescription
12MG/0.6ML (12MG/0.6ML)	SOLUTION;SUBCUTANEOUS	Prescription

156. Drug name - REMODULIN

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).

Pharsight

Drug Patents Expiring in 2029

1. Drug name - ABILIFY MYCITE KIT

2. Drug name - ACANYA

3. Drug name - ACTOPLUS MET

4. Drug name - ACUVAIL

5. Drug name - ALIQOPA

6. Drug name - ALUNBRIG

7. Drug name - ANGIOMAX

8. Drug name - ARNUITY ELLIPTA

9. Drug name - ATRIPLA

10. Drug name - AUVI-Q

11. Drug name - BAXDELA

12. Drug name - BELSOMRA

13. Drug name - BESIVANCE

14. Drug name - BRAFTOVI

15. Drug name - BREO ELLIPTA

16. Drug name - BRISDELLE

17. Drug name - BROMSITE

18. Drug name - BYDUREON

19. Drug name - CALDOLOR

20. Drug name - CAPLYTA

21. Drug name - CARNEXIV

22. Drug name - COLCRYS

23. Drug name - CONSENSI

24. Drug name - CONTRAVE

25. Drug name - COPIKTRA

26. Drug name - COTELLIC

27. Drug name - DAKLINZA

28. Drug name - DESYREL

29. Drug name - DEXILANT SOLUTAB

30. Drug name - DOVATO

31. Drug name - DUAKLIR PRESSAIR

32. Drug name - DURYSTA

33. Drug name - DUTREBIS

34. Drug name - DUZALLO

35. Drug name - DYANAVEL XR

36. Drug name - ELLA

37. Drug name - EMBEDA

38. Drug name - EPCLUSA

39. Drug name - ESBRIET

40. Drug name - EUCRISA

41. Drug name - EVOMELA

42. Drug name - EVOTAZ

43. Drug name - EVZIO

44. Drug name - EVZIO (AUTOINJECTOR)

45. Drug name - EXONDYS 51

46. Drug name - FARXIGA

47. Drug name - FERRIPROX

48. Drug name - FINACEA

49. Drug name - FIRMAGON

50. Drug name - FYARRO

51. Drug name - GALAFOLD

52. Drug name - GELNIQUE

53. Drug name - GEMTESA

54. Drug name - GENOSYL

55. Drug name - GENVOYA

56. Drug name - GIAPREZA

57. Drug name - GILOTRIF

58. Drug name - GIMOTI

59. Drug name - GIVLAARI

60. Drug name - GLYXAMBI

61. Drug name - HARVONI

62. Drug name - HORIZANT

63. Drug name - IBSRELA

64. Drug name - INBRIJA

65. Drug name - INCRUSE ELLIPTA

66. Drug name - INGREZZA

67. Drug name - INOMAX

68. Drug name - INTERMEZZO

69. Drug name - INVOKAMET

70. Drug name - INVOKAMET XR

71. Drug name - INVOKANA

72. Drug name - ISENTRESS

73. Drug name - ISTURISA

74. Drug name - IZBA

75. Drug name - JANUMET

76. Drug name - JARDIANCE

77. Drug name - JATENZO

78. Drug name - JENTADUETO